Omeros Receives Complete Response Letter From FDA For Biologics License Application For Narsoplimab In The Treatment Of HSCT-TMA
Omeros Corporation (NASDAQ:OMER) today announced that the company received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its Biologics License Application (BLA) for
The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Oct. 11)
JP Morgan Downgrades Omeros to Underweight
JP Morgan analyst Eric Joseph downgrades Omeros (NASDAQ:OMER) from Neutral to Underweight.
The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer’s Sleep Disorder Drug Filing Accepted For Review, Voyager’s Licensing Options Deal
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Oct. 5)
HC Wainwright & Co. Maintains Buy on Omeros, Lowers Price Target to $19
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Omeros (NASDAQ:OMER) with a Buy and lowers the price target from $32 to $19.
The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Oct. 4)